A Double-Blind, Randomized, Placebo-Controlled, Phase 1, Single-Dose, Dose-Escalating Trial of Long-Acting Recombinant Human IL-7 (NT-I7) for COVID-19

Official Title

Not Provided

Brief Summary

Not Provided

Detailed Description

Not Provided

Interventions

Not Provided

Eligibility Criteria

Not Provided

Locations

Not Provided

Contacts

Not Provided

Investigators

Not Provided

NCT Number

NCT04476290

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

A Double-Blind, Randomized, Placebo-Controlled, Phase 1, Single-Dose, Dose-Escalating Trial of Long-Acting Recombinant Human IL-7 (NT-I7) for COVID-19

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA